Delcath Systems (NASDAQ:DCTH) Price Target Raised to $24.00

Delcath Systems (NASDAQ:DCTH) had its price objective upped by HC Wainwright from $22.00 to $24.00 in a research report released on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Delcath Systems’ FY2029 earnings at $1.58 EPS.

Separately, Craig Hallum raised their target price on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.75.

Delcath Systems Stock Performance

NASDAQ DCTH opened at $13.00 on Friday. The stock has a 50-day simple moving average of $14.42 and a two-hundred day simple moving average of $11.72. The firm has a market capitalization of $415.66 million, a P/E ratio of -9.63 and a beta of 0.82. Delcath Systems has a fifty-two week low of $3.70 and a fifty-two week high of $16.97.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The company had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.96 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. During the same quarter in the previous year, the business posted ($0.48) EPS. As a group, analysts forecast that Delcath Systems will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On Delcath Systems

A number of institutional investors have recently modified their holdings of the business. Quarry LP acquired a new stake in Delcath Systems in the 4th quarter worth about $34,000. Quantbot Technologies LP acquired a new stake in Delcath Systems in the 4th quarter worth about $66,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Delcath Systems in the 3rd quarter worth about $102,000. Barclays PLC acquired a new stake in Delcath Systems in the 3rd quarter worth about $104,000. Finally, Jane Street Group LLC acquired a new stake in Delcath Systems in the 3rd quarter worth about $110,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.